Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTUS: Ipatasertib + Paclitaxel in mTNBC
NCT02162719Phase 2Completed
- Sponsor
- Genentech
- Start
- Aug 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of ipatasertib in triple negative breast cancer (TNBC), sponsored by Genentech. Started Aug 2014; status: completed.
02
Drugs
ipatasertib
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02162719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02162719.